Enhanced levels of eIF2α phosphorylation have also been described in other solid tumor entities (e.g., lung cancer, PDAC, breast cancer) pointing to the possibility that modulation of the eIF2B complex might induce a vulnerability in other types of cancer (Bai et al, 2021; Ghaddar et al, 2021; Koromilas, 2015; Shin et al, 2022). The gene discussed is EIF2A; the disease is lung cancer.